Finance Your Drug Testing Business Acquisition with an SBA Loan
Drug testing companies serving DOT-regulated industries and employer compliance programs are strong SBA-eligible candidates. Here is how to structure your acquisition financing and close with confidence.
Find SBA-Eligible Drug Testing Services BusinessesSBA Overview for Drug Testing Services Acquisitions
Drug testing services businesses — including specimen collection networks, DOT consortium managers, and Medical Review Officer practices — are well-suited for SBA 7(a) acquisition financing. These businesses generate non-discretionary, recurring revenue from employer compliance mandates under federal DOT and SAMHSA regulations, which lenders view favorably when underwriting debt service coverage. A typical lower middle market drug testing acquisition in the $1M–$5M revenue range may involve a purchase price of $1.75M–$8M depending on EBITDA margins and client contract quality. SBA 7(a) loans allow buyers to finance up to 90% of the acquisition price, preserve working capital, and negotiate seller notes or earnouts for the remaining equity gap. Because drug testing revenue is anchored by regulatory requirements rather than discretionary spending, SBA lenders generally treat these cash flows as durable — provided the buyer can demonstrate a clean compliance record, diversified employer client base, and a credible transition plan that reduces owner dependency.
Down payment: SBA 7(a) loans for drug testing business acquisitions typically require a 10%–15% buyer equity injection at closing. For a $3M acquisition of a DOT-compliant collection network, that means $300K–$450K in equity from the buyer. Lenders often structure the remaining gap with a seller note of 5%–10% — typically $150K–$300K held at subordinated terms for 24 months — which satisfies SBA equity injection requirements when the seller note is on full standby. Earnouts tied to post-close client retention are common in drug testing deals given owner dependency risk, but most SBA lenders will not count earnout consideration toward the equity injection. Buyers should plan for additional closing costs of $25K–$60K covering SBA guarantee fees, lender origination, appraisals, environmental screens if real property is involved, and legal fees for the asset purchase agreement and non-compete documentation.
SBA Loan Options
SBA 7(a) Standard Loan
10-year term for business acquisitions; variable rate typically at Prime plus 2.25%–2.75%; fully amortizing with no balloon payment
$5,000,000
Best for: Acquisitions of established drug testing companies with $500K–$2M in EBITDA, a documented employer client base under written contracts, and strong debt service coverage — the most common structure for lower middle market drug testing deals
SBA 7(a) Small Loan
10-year term; streamlined underwriting with reduced documentation requirements; variable rate at Prime plus 2.25%–2.75%
$500,000
Best for: Smaller collection site acquisitions or tuck-in purchases of a single-market drug testing operation, particularly where goodwill and client lists are the primary assets being acquired
SBA 504 Loan
10- or 20-year fixed rate on CDC portion; bank portion typically 10 years; requires 10% borrower equity injection
$5,500,000 (combined CDC and bank portions)
Best for: Drug testing acquisitions that include a significant real property component such as a standalone occupational health clinic or owned collection facility — less common in pure-service drug testing deals where most value is intangible
Eligibility Requirements
- The target business must be a for-profit U.S.-based drug testing operation with three years of verifiable financial history, including separation of collection revenue from pass-through lab and MRO charges so lenders can assess true operating margin
- The buyer must inject a minimum of 10% equity at close, typically sourced from personal funds, a seller note, or a combination — lenders will require documentation that the equity is not borrowed against other assets
- The acquiring entity must qualify as a small business under SBA size standards, which for drug testing and occupational health services generally means under $8M in average annual receipts or under 150 employees depending on NAICS classification
- All collector certifications, DOT qualifications, and SAMHSA-compliant lab partnerships must be current and transferable to the new ownership entity — lapsed certifications at closing can trigger lender conditions or deal delays
- The buyer must have relevant management experience in healthcare operations, HR compliance, occupational health, or a closely related field, as SBA lenders require evidence that the acquirer can operate a regulated drug testing business without the seller
- The business must have a clean regulatory history with no open DOT audit findings, SAMHSA violations, HIPAA consent orders, or unresolved state occupational health licensing issues that could impair future revenue or create contingent liabilities
Step-by-Step Process
Identify and Qualify the Target Drug Testing Business
Source acquisition targets through healthcare-focused business brokers, occupational health M&A advisors, or direct outreach to DOT consortium operators and collection network owners. Request a confidential information memorandum and confirm the business has at least $500K in EBITDA, a diversified employer client base with no single account exceeding 20% of revenue, and current DOT collector certifications and SAMHSA-certified lab relationships. Preliminary review of three years of P&Ls should separate collection fees from pass-through lab charges to assess true margin.
Submit a Letter of Intent and Negotiate Deal Structure
Submit a non-binding LOI specifying the purchase price range based on a 3.5x–6x EBITDA multiple, proposed deal structure including SBA 7(a) primary debt, seller note, and any earnout tied to client retention, and key conditions including regulatory compliance confirmation and transition period length. Negotiate a 12–24 month non-compete and transition agreement with the seller, which SBA lenders will require to protect the goodwill being financed. Confirm the seller is willing to provide a subordinated seller note if the equity gap requires it.
Engage an SBA Lender with Healthcare or Business Services Experience
Approach SBA Preferred Lender Program banks or SBA-active credit unions with experience financing occupational health or B2B compliance service acquisitions. Provide the lender with three years of business tax returns, reviewed or compiled financials, a buyer resume demonstrating healthcare or HR compliance management experience, and a preliminary business plan outlining your transition strategy for key employer accounts and MRO coordination workflows. Lenders will scrutinize pass-through revenue carefully — be prepared to explain lab and MRO cost structure in detail.
Complete Due Diligence on Regulatory Compliance and Client Contracts
Engage a healthcare attorney and CPA experienced in occupational health transactions to conduct due diligence on DOT and SAMHSA compliance history, collector certification status, lab and MRO vendor agreements including change-of-control provisions, and client contract terms. Verify there are no open citations, consent orders, or pending audits. Analyze client concentration by industry segment — transportation, construction, healthcare, and government — and model churn scenarios to stress-test SBA debt service coverage. Confirm that chain-of-custody software, LIMS integrations, and electronic reporting systems are transferable and current.
Receive SBA Loan Commitment and Finalize Purchase Agreement
Once the lender issues a conditional loan commitment, work with your attorney to finalize the asset purchase agreement allocating consideration across goodwill, client lists, equipment, and non-compete. Confirm that all collector certifications and state occupational health licenses are transferable or will be reissued to the acquiring entity before close. Ensure the seller note is documented as subordinated to the SBA lender and on full standby for the first 24 months per SBA guidelines. Coordinate with the lender on SBA guarantee fee payment and closing fund disbursement.
Close and Execute Transition Plan
At closing, execute the transition and consulting agreement with the seller to manage warm handoffs of key corporate accounts and DOT consortium clients. Notify all employer clients of the ownership change as required under applicable contracts and any state occupational health regulations. Reissue or transfer all collector certifications, DOT authorizations, and SAMHSA lab partnership agreements under the new entity. Activate your client retention protocol — the majority of SBA earnouts in drug testing deals are tied to 12-month post-close revenue thresholds, making early client communication critical to financial performance.
Common Mistakes
- ✗Underestimating pass-through revenue distortion: many drug testing businesses report $2M–$4M in top-line revenue but carry $800K–$1.5M in direct lab and MRO pass-through costs. Buyers who fail to recast financials to isolate true collection and MRO service revenue will overstate EBITDA, overbid on valuation, and present an inaccurate debt service coverage picture to their SBA lender
- ✗Ignoring collector certification transferability: DOT collector certifications and state occupational health licenses are typically issued to individuals or specific entities. Failing to confirm these are transferable — or that the buyer can obtain equivalent credentials before close — can delay or derail SBA funding at the final stage
- ✗Accepting a seller note on active repayment terms: SBA lenders require seller notes to be on full standby for a minimum of 24 months. Buyers who negotiate a seller note without understanding this requirement often have to renegotiate terms after receiving the lender's commitment letter, creating friction and deal delays
- ✗Neglecting client contract assignment provisions: many drug testing employer contracts include change-of-control or assignment clauses that require client consent before transferring the agreement to a new owner. Buyers who do not audit these provisions pre-close risk losing key accounts immediately after funding, directly undermining SBA debt service coverage assumptions
- ✗Overlooking regulatory red flags during due diligence: unresolved DOT audit findings, expired SAMHSA lab certifications, or undisclosed HIPAA incidents discovered after closing can trigger indemnification disputes, regulatory penalties, and lender covenant violations. SBA lenders will require a clean compliance representation at close — buyers who skip regulatory due diligence are accepting liability that could exceed the acquisition price
Lender Tips
- Target SBA Preferred Lender Program banks with a track record in occupational health, laboratory services, or B2B compliance businesses — generalist SBA lenders unfamiliar with drug testing revenue models will often misclassify pass-through lab revenue as operating income, creating underwriting errors that slow approval
- Prepare a detailed revenue recast before your first lender meeting that separates collection fees, MRO service revenue, and pass-through lab charges, and shows three years of adjusted EBITDA — lenders who understand the margin structure of drug testing businesses will move faster and structure more favorable terms
- Obtain a third-party business valuation from a certified valuator with healthcare or occupational health transaction experience — SBA lenders on deals above $250K in goodwill will require an independent valuation, and one that properly accounts for DOT contract value and SAMHSA lab relationships will support a stronger loan-to-value position
- Document your post-close management plan in detail, specifically naming the staff members who will take over key account management and MRO coordination responsibilities previously handled by the seller — lenders view owner dependency as the primary default risk in drug testing acquisitions and will require evidence of operational continuity
- Ask your lender early whether they will allow a seller note to count toward the equity injection and under what standby conditions — in drug testing deals where the seller holds key client relationships, a seller note of 5%–10% on 24-month standby is a standard and lender-accepted mechanism to bridge the equity gap without requiring additional buyer cash at close
Find SBA-Ready Drug Testing Services Businesses
Pre-screened acquisition targets with verified financials — free to join.
SBA Loan Calculator
Estimate your monthly payment for a Drug Testing Services acquisition
Standard for acquisitions
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
Are drug testing businesses eligible for SBA 7(a) acquisition loans?
Yes. Drug testing services companies — including DOT specimen collection networks, employer compliance programs, DOT consortium managers, and MRO practices — are generally SBA-eligible for-profit businesses. Lenders view their non-discretionary, regulation-driven revenue favorably when underwriting debt service coverage. The key eligibility factors are clean financial documentation separating true operating revenue from pass-through lab charges, current regulatory certifications, and a buyer with relevant management experience in healthcare, HR compliance, or occupational health operations.
How much do I need to put down to buy a drug testing company with an SBA loan?
SBA 7(a) loans for drug testing acquisitions typically require a 10%–15% equity injection from the buyer. On a $3M deal, that is $300K–$450K at closing. Sellers in drug testing transactions frequently contribute a 5%–10% subordinated seller note — typically $150K–$300K — that counts toward the equity requirement when structured on full standby for 24 months per SBA guidelines. Buyers should also budget $25K–$60K for SBA guarantee fees, legal costs, and third-party valuation.
How do SBA lenders evaluate pass-through lab revenue in drug testing businesses?
SBA lenders underwriting drug testing acquisitions must distinguish between collection service revenue — which carries meaningful margin — and pass-through charges for laboratory analysis and MRO review, which often carry little to no net margin. Lenders will recast three years of financials to isolate adjusted EBITDA based solely on the business's own service revenue. Buyers who present a clean revenue recast upfront — showing collection fees, DOT consortium management fees, and MRO service income separately from lab pass-throughs — will move through underwriting significantly faster and avoid lender confusion that can stall or reduce loan approval.
Can I use an SBA loan if the seller wants an earnout tied to client retention?
Yes, earnouts are common in drug testing acquisitions where owner dependency creates post-close revenue risk. However, SBA lenders will not count earnout consideration toward your required equity injection, and they will typically exclude contingent earnout payments from the financed purchase price. The earnout must be clearly documented in the purchase agreement with specific client retention triggers — often 80%–90% of trailing twelve-month revenue retained over 12 months post-close. Structure the earnout as a separate contingent payment outside the SBA-financed portion to avoid lender complications.
What regulatory issues can block SBA financing for a drug testing acquisition?
Open DOT audit findings, expired or non-transferable collector certifications, unresolved SAMHSA lab compliance issues, undisclosed HIPAA violations, or pending state occupational health licensing actions can each block or delay SBA loan approval. Lenders will require a regulatory compliance representation at closing and may condition funding on resolution of any cited issues. Buyers should conduct thorough regulatory due diligence — including requesting five years of DOT and SAMHSA audit history from the seller — before submitting a loan application to avoid discovering deal-breaking compliance gaps during underwriting.
What EBITDA multiples should I expect to pay for a drug testing business?
Lower middle market drug testing businesses typically trade at 3.5x–6x EBITDA. Businesses at the higher end of that range have diversified employer client rosters under multi-year contracts, DOT consortium management generating recurring subscription-like revenue, proprietary mobile collection fleets, clean compliance histories, and scalable technology platforms with electronic chain-of-custody and HR system integrations. Businesses closer to 3.5x often have significant owner dependency, month-to-month employer contracts, or revenue concentrated in one or two large accounts. SBA lenders will require the purchase price to be supported by an independent third-party valuation for any transaction where financed goodwill exceeds $250K.
How long does it take to close an SBA-financed drug testing acquisition?
Most SBA 7(a)-financed drug testing acquisitions take 90–120 days from signed LOI to close. The process includes 2–4 weeks for lender application and initial underwriting, 4–6 weeks for due diligence on regulatory compliance and client contracts, 2–3 weeks for SBA guarantee approval, and 1–2 weeks for closing documentation. Deals that surface regulatory compliance issues, require client consent for contract assignment, or involve complex lab and MRO vendor agreement reviews can take 120–150 days. Engaging a healthcare-focused M&A attorney and an SBA lender experienced in occupational health transactions from the start of the process is the most reliable way to compress the timeline.
More Drug Testing Services Guides
More SBA Loan Guides
Start Finding Drug Testing Services Deals Today — Free to Join
Find SBA-eligible targets, score seller motivation, and get AI-written outreach in one platform.
Create your free accountNo credit card required